Meeting
2020 Gastrointestinal Cancers Symposium
Prognostic factor of nivolumab for advanced gastric cancer patients with poor performance status patients.
Authors
Toshihiko Matsumoto
Himeji Red Cross Hospital, Himeji, Japan
Toshihiko Matsumoto , Ukyo Okazaki , Yusuke Kurioka , Shogo Kimura , Takao Tsuzuki , Shinjiro Takagi , Masahiro Takatani , Hirofumi Morishita
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 391)
Abstract #
391
Poster Bd #
F2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The new prognostic index of advanced gastric cancer using the data from JCOG1013.
First Author: Daisuke Takahari
Poster
2022 ASCO Gastrointestinal Cancers Symposium
REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC).
First Author: Tomohiro Matsushima
Poster
2020 Gastrointestinal Cancers Symposium
Retrospective analysis for efficacy and safety of nivolumab in advanced gastric cancer patients (pts) with malignant ascites.
First Author: Akinori Sugaya
Poster
2016 ASCO Annual Meeting
Validation of the JCOG prognostic index in advanced gastric cancer of the SPIRITS and G-SOX trials, using individual patient data.
First Author: Daisuke Takahari